1. Generics Bulletin
  2. >>Archive

AbbVie sees 80% discounting

Discounts due to biosimilar competition have risen as high as 80% in Europe, according to AbbVie chairman and chief executive officer Richard Gonzalez. Noting that Remicade (infliximab) and Enbrel (etanercept) were the “analogs” that AbbVie had used to plan for the onset of biosimilar competition to its Humira (adalimumab) brand in Europe, he observed that discounting on infliximab and etanercept “ranges from as low as 10% to as high as around 80%”, with “the higher discounting seen in the Nordic tender countries”.

Discounts due to biosimilar competition have risen as high as 80% in Europe, according to AbbVie chairman and chief executive officer Richard Gonzalez. Noting that Remicade (infliximab) and Enbrel (etanercept) were the “analogs” that AbbVie had used to plan for the onset of biosimilar competition to its Humira (adalimumab) brand in Europe, he observed that discounting on infliximab and etanercept “ranges from as low as 10% to as high as around 80%”, with “the higher discounting seen in the Nordic tender countries”.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin